_PurpleBiotech's profile picture. Purple Biotech (NASDAQ/TASE: PPBT) is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion & drug resistance

Purple Biotech

@_PurpleBiotech

Purple Biotech (NASDAQ/TASE: PPBT) is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion & drug resistance

$PPBT Purple Biotech Achieves Toxicology Milestone Demonstrating an Expanded Therapeutic Window for CAPTN-3 Platform Tri-specific Antibody, IM1240 Read the full press release here: globenewswire.com/news-release/2…

_PurpleBiotech's tweet image. $PPBT Purple Biotech Achieves Toxicology Milestone Demonstrating an Expanded Therapeutic Window for CAPTN-3 Platform Tri-specific Antibody, IM1240

Read the full press release here: globenewswire.com/news-release/2…

$PPBT Purple Biotech Reports Positive New Preclinical Data Demonstrating Multi-Arm Anti-Tumor Activity Across Two CAPTN-3 Tri-Specific Antibodies at ESMO Immuno-Oncology Congress 2025 Read the full press release here: globenewswire.com/news-release/2…

_PurpleBiotech's tweet image. $PPBT Purple Biotech Reports Positive New Preclinical Data Demonstrating Multi-Arm Anti-Tumor Activity Across Two CAPTN-3 Tri-Specific Antibodies at ESMO Immuno-Oncology Congress 2025

Read the full press release here: globenewswire.com/news-release/2…

$PPBT Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress Read the full press release here: globenewswire.com/news-release/2…

_PurpleBiotech's tweet image. $PPBT Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress

Read the full press release here: globenewswire.com/news-release/2…

We are thrilled to announce the initiation of the Phase 2 study for CM24 as a potential 2L treatment for patients with #PDAC, expanding the potential for treatment for #patients while extending our cash runway through 2024. More: tinyurl.com/522f8ccs #oncology #cancer #PDAC


We are pleased to share interim safety & efficacy in our Phase 1b Study of CM24 in Combination w/ Opdivo at #AACR22 saw 1 confirmed PR & 3 SD in patients with advanced pancreatic cancer and PTC. 9 patients still in study follow-up #oncology #Cancer bit.ly/3KxZjce

_PurpleBiotech's tweet image. We are pleased to share interim safety & efficacy in our Phase 1b Study of CM24 in Combination w/ Opdivo at #AACR22 saw 1 confirmed PR & 3 SD in patients with advanced pancreatic cancer and PTC. 9 patients still in study follow-up 

#oncology #Cancer

bit.ly/3KxZjce

We are pleased to issue the following letter from its Chief Executive Officer, Isaac Israel, to its shareholders: bit.ly/3guxNz4 #cancerresearch #curecancer #oncology

_PurpleBiotech's tweet image. We are pleased to issue the following letter from its Chief Executive Officer, Isaac Israel, to its shareholders: bit.ly/3guxNz4

#cancerresearch #curecancer #oncology

Purple is excited to announce that NT219 was well-tolerated in initial clinical data from our ongoing Phase 1/2 study with a partial response observed in a patient with refractory GE junction cancer #CancerResearch #ASCO21 #Curecancer bit.ly/34OKvCQ

_PurpleBiotech's tweet image. Purple is excited to announce that NT219 was well-tolerated in initial clinical data from our ongoing Phase 1/2 study with a partial response observed in a patient with refractory GE junction cancer #CancerResearch #ASCO21 #Curecancer bit.ly/34OKvCQ

Purple Biotech to present interim data from our ongoing Phase 1/2 clinical trial of NT219, a monotherapy for the treatment of solid tumors that has the potential to help people living with hard-to-treat cancers, on June 4 #ASCO21 #cancer #cancerresearch #oncologyresearch

_PurpleBiotech's tweet image. Purple Biotech to present interim data from our ongoing Phase 1/2 clinical trial of NT219, a monotherapy for the treatment of solid tumors that has the potential to help people living with hard-to-treat cancers, on June 4 #ASCO21 #cancer #cancerresearch #oncologyresearch

Happy to present new data supporting NT219's MOA, a dual inhibitor, novel SM targeting IRS1/2 & STAT3 at the Epigenetics and Metabolism AACR Virtual Conference by researchers at TASMC & Tel-Aviv University #cancer #tasmc finance.yahoo.com/news/mechanism…


Proud to present the anti-tumor activity of NT219 in pembrolizumab-resistant head and neck cancer PDX models at AACR 2020 virtual meeting II #Cancer #AACR2020 #keytdura #oncology #headandneckcancer

_PurpleBiotech's tweet image. Proud to present the anti-tumor activity of NT219 in pembrolizumab-resistant head and neck cancer PDX models at AACR 2020 virtual meeting II #Cancer #AACR2020 #keytdura #oncology #headandneckcancer

Presenting phase 1 data on CM-24 in patients with advanced cancer at ASCO 2020 Virtual Meeting #ASCO20 #CEACAM1 #oncology #Immunotherapy

_PurpleBiotech's tweet image. Presenting phase 1 data on CM-24 in patients with advanced cancer at ASCO 2020 Virtual Meeting #ASCO20 #CEACAM1 #oncology #Immunotherapy

We are glad to announce U.S. FDA IND acceptance to conduct a phase 1/2 clinical trial of NT-219 for treatment of recurrent or metastatic solid tumors and head and neck cancer. tiny.cc/sfnjpz #cancer #headandneckcancer #solidtumors #clinicaltrials

_PurpleBiotech's tweet image. We are glad to announce U.S. FDA IND acceptance to conduct a phase 1/2 clinical trial of NT-219 for treatment of recurrent or metastatic solid tumors and head and neck cancer. tiny.cc/sfnjpz #cancer #headandneckcancer #solidtumors #clinicaltrials

Proud to announce the U.S. commercial launch of Consensi™, designed for the simultaneous treatment of hypertension and osteoarthritis pain. Consensi™ is being sold by Burke Therapeutics, the marketing partner of our distributor, Coeptis Pharmaceuticals. tiny.cc/qjbhpz

_PurpleBiotech's tweet image. Proud to announce the U.S. commercial launch of Consensi™, designed for the simultaneous treatment of hypertension and osteoarthritis pain. Consensi™ is being sold by Burke Therapeutics, the marketing partner of our distributor, Coeptis Pharmaceuticals. tiny.cc/qjbhpz

Proud to present today our expanded planned NT-219 clinical program for difficult to treat cancers, at the 2020 Multidisciplinary Head and Neck Cancers Symposium, being held in Scottsdale, Arizona #cancer #headandneckcancer #HNCS20

_PurpleBiotech's tweet image. Proud to present today our expanded planned NT-219 clinical program for difficult to treat cancers, at the 2020 Multidisciplinary Head and Neck Cancers Symposium, being held in Scottsdale, Arizona #cancer #headandneckcancer #HNCS20

Most relapses of #cancer are attributed to #drugresistance. We are developing #oncology therapies to overcome tumor drug resistance, enhance treatment response and slow tumor progression. Learn more about our pipeline: bit.ly/2LkcnW2

_PurpleBiotech's tweet image. Most relapses of #cancer are attributed to #drugresistance. We are developing #oncology therapies to overcome tumor drug resistance, enhance treatment response and slow tumor progression. Learn more about our pipeline: bit.ly/2LkcnW2

Loading...

Something went wrong.


Something went wrong.